132 related articles for article (PubMed ID: 16150512)
1. Development and immunochemical evaluation of antibodies Y for the poorly immunogenic polypeptide prothymosin alpha.
Klimentzou P; Paravatou-Petsotas M; Zikos C; Beck A; Skopeliti M; Czarnecki J; Tsitsilonis O; Voelter W; Livaniou E; Evangelatos GP
Peptides; 2006 Jan; 27(1):183-93. PubMed ID: 16150512
[TBL] [Abstract][Full Text] [Related]
2. Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody.
Klimentzou P; Drougou A; Fehrenbacher B; Schaller M; Voelter W; Barbatis C; Paravatou-Petsotas M; Livaniou E
J Histochem Cytochem; 2008 Nov; 56(11):1023-31. PubMed ID: 18711212
[TBL] [Abstract][Full Text] [Related]
3. Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100-109) in sera of mice infected with bacteria.
Samara P; Kalbacher H; Ioannou K; Radu DL; Livaniou E; Promponas VJ; Voelter W; Tsitsilonis O
J Immunol Methods; 2013 Sep; 395(1-2):54-62. PubMed ID: 23831611
[TBL] [Abstract][Full Text] [Related]
4. The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients.
Skopeliti M; Voutsas IF; Klimentzou P; Tsiatas ML; Beck A; Bamias A; Moraki M; Livaniou E; Neagu M; Voelter W; Tsitsilonis OE
Cancer Immunol Immunother; 2006 Oct; 55(10):1247-57. PubMed ID: 16453152
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Immunodetection of Prothymosin Alpha in Normal and Pathological Conditions.
Karachaliou CE; Kalbacher H; Voelter W; Tsitsilonis OE; Livaniou E
Curr Med Chem; 2020; 27(29):4840-4854. PubMed ID: 31389310
[TBL] [Abstract][Full Text] [Related]
6. In vivo biodistribution and imaging studies with a
Karachaliou CE; Triantis C; Liolios C; Palamaris L; Zikos C; Tsitsilonis OE; Kalbacher H; Voelter W; Loudos G; Papadopoulos M; Pirmettis I; Livaniou E
Eur J Pharm Biopharm; 2017 Apr; 113():188-197. PubMed ID: 28087377
[TBL] [Abstract][Full Text] [Related]
7. [Prothymosin alpha and tumor: current status and perspective].
Wang M; Pan JY
Ai Zheng; 2007 Mar; 26(3):333-6. PubMed ID: 17355803
[TBL] [Abstract][Full Text] [Related]
8. Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha.
Lal A; Kawai T; Yang X; Mazan-Mamczarz K; Gorospe M
EMBO J; 2005 May; 24(10):1852-62. PubMed ID: 15861128
[TBL] [Abstract][Full Text] [Related]
9. A radioimmunoassay for parathymosin alpha using antibodies to synthetic N-terminal peptide 1-30.
Tsitsiloni OE; Yialouris PP; Heimer EP; Felix AM; Evangelatos GP; Soteriadis-Vlahos C; Stiakakis J; Hannappel E; Haritos AA
J Immunol Methods; 1988 Oct; 113(2):175-84. PubMed ID: 3049827
[TBL] [Abstract][Full Text] [Related]
10. Characterization of two thymosins as immune-related genes in common carp (Cyprinus carpio L.).
Xiao Z; Shen J; Feng H; Liu H; Wang Y; Huang R; Guo Q
Dev Comp Immunol; 2015 May; 50(1):29-37. PubMed ID: 25596145
[TBL] [Abstract][Full Text] [Related]
11. Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils.
Karachaliou CE; Liolios C; Triantis C; Zikos C; Samara P; Tsitsilonis OE; Kalbacher H; Voelter W; Papadopoulos M; Pirmettis I; Livaniou E
Int J Pharm; 2015; 486(1-2):1-12. PubMed ID: 25796124
[TBL] [Abstract][Full Text] [Related]
12. Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy.
Ioannou K; Samara P; Livaniou E; Derhovanessian E; Tsitsilonis OE
Cancer Immunol Immunother; 2012 May; 61(5):599-614. PubMed ID: 22366887
[TBL] [Abstract][Full Text] [Related]
13. Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction.
Teixeira A; Yen B; Gusella GL; Thomas AG; Mullen MP; Aberg J; Chen X; Hoshida Y; van Bakel H; Schadt E; Basler CF; García-Sastre A; Mosoian A
J Infect Dis; 2015 May; 211(9):1467-75. PubMed ID: 25404520
[TBL] [Abstract][Full Text] [Related]
14. Identification of receptors for prothymosin alpha on human lymphocytes.
Piñeiro A; Begoña Bugia M; Pilar Arias M; Cordero OJ; Nogueira M
Biol Chem; 2001 Oct; 382(10):1473-82. PubMed ID: 11727831
[TBL] [Abstract][Full Text] [Related]
15. Prothymosin alpha associates with the oncoprotein SET and is involved in chromatin decondensation.
Karetsou Z; Martic G; Tavoulari S; Christoforidis S; Wilm M; Gruss C; Papamarcaki T
FEBS Lett; 2004 Nov; 577(3):496-500. PubMed ID: 15556635
[TBL] [Abstract][Full Text] [Related]
16. [Prothyomosin alpha interaction with KEAP1 doesn't lead to prothymosin alpha ubiquination and degradation].
Mel'nikov SV; Evstaf'eva AG; Vartapetian AB
Mol Biol (Mosk); 2007; 41(5):868-75. PubMed ID: 18240569
[TBL] [Abstract][Full Text] [Related]
17. Stress-induced non-vesicular release of prothymosin-α initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage.
Matsunaga H; Ueda H
Cell Death Differ; 2010 Nov; 17(11):1760-72. PubMed ID: 20467443
[TBL] [Abstract][Full Text] [Related]
18. Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription.
Karetsou Z; Kretsovali A; Murphy C; Tsolas O; Papamarcaki T
EMBO Rep; 2002 Apr; 3(4):361-6. PubMed ID: 11897665
[TBL] [Abstract][Full Text] [Related]
19. Regional distribution and cell type-specific subcellular localization of Prothymosin alpha in brain.
Halder SK; Ueda H
Cell Mol Neurobiol; 2012 Jan; 32(1):59-66. PubMed ID: 21750924
[TBL] [Abstract][Full Text] [Related]
20. Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?
Samara P; Ioannou K; Tsitsilonis OE
Vitam Horm; 2016; 102():179-207. PubMed ID: 27450735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
